Key facts
- This page summarizes Michael Serruya's Form 4 filing for MedMen Enterprises, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 09 Mar 2022, 19:21.
Michael Serruya - 04 Mar 2022 Form 4 Insider Report for MedMen Enterprises, Inc.
- Reporting relationship
- Chief Executive Officer, Director, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 04 Mar 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 09 Mar 2022, 19:21:15 UTC
- Prior SEC filing
- 13 Jan 2022
- Next SEC filing
- 31 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Serruya
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael Serruya filed Form 4 for MedMen Enterprises, Inc. on 09 Mar 2022.
Change
- Previous filing in this sequence was filed on 13 Jan 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MMNFF
transaction
Derivative
Top-Up Warrant
Other
- Transaction value
- $0
- Shares
- +1,565,140
- Change %
- Price
- $0.000000
- Shares after
- 1,565,140
- Date
- 04 Mar 2022
- Ownership
- See footnotes
- Underlying class
- Class B Subordinate Voting Shares
- Underlying amount
- 1,565,140
- Exercise price
- $0.1615
- Footnotes
- F1, F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Top-Up Warrants exercisable for Class B Subordinate Voting Shares ("Shares") were issued by MedMen Enterprises Inc. ("MedMen") pursuant to the terms of the Fourth Amended and Restated Securities Purchase Agreement dated August 17, 2021 (the "Convertible Facility") in connection with the issuance of Shares by MedMen as part of the Sixth Modification to its Senior Secured Commercial Loan Agreement, which automatically triggered the right of holders of convertible notes issued under the Convertible Facility to be issued on an involuntary basis five-year warrants in order to maintain their pro rata ownership interest (on a partially diluted basis) in Shares.
Footnote F2
The Top-Up Warrants expire on the earlier of the date that is (i) February 2, 2027, and (ii) the date that is the later of (A) 90 days after the Triggering Event (as defined in the Convertible Facility), or (B) if later than the date determined pursuant to the immediately preceding clause (A), 90 days after the issuance of all Shares issued pursuant to the Top-Up Warrant Triggering Event (as defined therein).
Footnote F3
The Top-Up Warrants are owned directly by Superhero Acquisition L.P. ("LP"). Superhero Acquisition Corp. ("Corp.") is the general partner of LP. MOS Holdings Inc. ("MOS") owns approximately one-third of the outstanding equity interests in Corp. S5 Holdings Limited Liability Company, which is controlled by Michael Serruya, has an 8% in LP. Accordingly, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, Mr. Serruya and MOS may each be deemed a beneficial owner with respect to securities held of record by LP and has shared voting and investment power with respect to such securities. Securities reported represent the proportionate amount attributed to Mr. Serruya and MOS.
Footnote F4
Each reporting person disclaims beneficial ownership of these securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.